Uncommon Therapeutics
A Disease Focused Biotech, Building Multiple Billion Dollar Drugs
Uncommon Therapeutics is active in the healthcare space based in San Francisco, CA, USA.
Profile
Our founder Noah, an experienced tech entrepreneur, was directly impacted by a severe genetic disease when his daughter was diagnosed with Rett Syndrome, a disease that afflicts 1 in 10,000 girls. Using an innovative polytherapy strategy, we’ve successfully improved her quality of life, and have designed new therapeutics that each could be worth billions and together could deliver a cure.
Within the healthcare space, the company focuses on its core offering rather than a broad product line.
Its base of operations is San Francisco, CA, USA.
Directory data places it at the Winter 2025 stage.
Recorded headcount: 2 employees.
Directory analysis
Uncommon Therapeutics is a U.S. biotech company headquartered in San Francisco that focuses on developing disease‑specific therapeutics for rare genetic disorders, notably Rett syndrome. The firm employs a polytherapy strategy to create multiple drug candidates, each potentially worth billions of dollars.
Positioning: With a very small team and no disclosed funding, the company is in an early‑stage position within the niche rare‑disease therapeutics market, aiming to deliver high‑impact treatments through its polytherapy platform.
Note: Founder’s personal experience with Rett syndrome drives the company’s mission.
Auto-generated directory analysis from public data · updated 9 Oct 2026. Informational only, not investment advice.
| Sector | Healthcare |
|---|---|
| Headquarters | San Francisco, CA, USA |
| Country | USA |
| Employees | 2 |
| Stage | Winter 2025 |
Website: uncommontherapeutics.com
Browse related
Create a free account